Leveraging AI, the new offering assists pharmaceutical companies in enhancing their interaction with patients. Credit: Mdisk/Shutterstock.

AllazoHealth has introduced AI-enabled dynamic modular content to enhance initiation and medication adherence by personalising patient communications.

Leveraging AI, the new technology will assist pharmaceutical companies in enhancing patient interaction.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The solution customises communications at both the individual patient and modular levels, enabling pharmaceutical enterprises to deliver highly targeted messages to individuals on a large scale.

Medication non-adherence is a key issue within the pharmaceutical industry, and often leads to higher rates of hospital admissions, poorer health outcomes and heightened morbidity rates.

Using dynamic modular content, which includes a variety of interchangeable modules such as subject lines, content blocks, email preview texts, images and calls to action, pharmaceutical marketers can design more tailored patient outreach.

See Also:

AI-enabled dynamic modular content can predict individual medication behaviours and aids in tailoring the most suitable content, timing, channels and frequency of communication to encourage the patient’s next best action.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AllazoHealth’s offering leverages a pharmaceutical company’s pre-approved, legally and medically sanctioned modules to dynamically personalise and streamline content, aiding patients in starting and adhering to therapies for improved health outcomes.

The solution uses wide-ranging datasets and years of cumulative data from millions of patient interactions, including more than 275 million communications made through email, phone and text messages.

This vast data pool, which includes more than 500 predictors of human behaviour, is used to refine models and enhance the effectiveness of patient communications.

AllazoHealth CEO William Grambley stated: “Healthcare consumers want to be understood as individuals. Pharmaceutical companies that excel at personalisation are exceeding their goals because their customers are more engaged.

“Our AI-enabled dynamic modular content helps pharmaceutical companies effectively predict the most relevant information for each specific patient – at the right time and in the ways they prefer to receive it – helping boost medication initiation, adherence, compliance and patient health outcomes.”